Literature DB >> 28982331

Plasma Exosomal miR-422a and miR-125b-2-3p Serve as Biomarkers for Ischemic Stroke.

Dong-Bin Li1, Jing-Li Liu1, Wei Wang1, Ru-Ying Li1, Dong-Ju Yu1, Xiao-Yan Lan2, Jin-Pin Li1.   

Abstract

BACKGROUND: MircroRNA (MiRNA) levels are associated with disease pathophysiology and are high in plasma exosomes. Plasma exosomal miRNAs serve as potential therapeutic targets and diagnosis biomarkers in some diseases but few studies have examined them in Ischemic Stroke (IS). Therefore, we explored the potential predictive value of plasma exosomal miR-422a and miR-125b-2-3p in different IS phases (acute and subacute phases).
METHODS: Fifty-five IS patients and 25 age and sex matched healthy controls were recruited. Patients were classified into two groups: 27 patients in acute phase (days 1-3) and 28 patients in subacute phase (days 4-14). The plasma exosomal levels of miR-422a and miR-125b-2-3p were examined via quantitative real-time polymerase chain reaction (qRT-PCR). The Areas Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve were constructed to evaluate the diagnostic accuracy of these miRNAs in IS.
RESULTS: The expression levels of plasma exosomal miR-422a and miR-125b-2-3p were significantly decreased in the subacute phase group (P<0.001, P<0.001, respectively), and the miR-422a levels were increased in the acute phase group (P<0.005) as compared to the controls. Additionally, the expression levels of plasma exosomal miR-422a and miR-125b-2-3p were significantly decreased in the subacute phase group than in the acute phase group (P<0.001, P<0.005, respectively). ROC analysis showed high AUC values for miR-422a and miR-125b-2-3p in the subacute phase group as compared to those in healthy controls: 0.971 and 0.889, respectively, and miR-422a in the acute phase group as compared to healthy controls were 0.769.
CONCLUSION: Plasma exosomal miR-422a and miR-125b-2-3p may serve as blood-based biomarkers for monitoring and diagnosing in IS patients, with plasma exosomal miR-422a showing the best diagnostic value. The use of these two plasma exosomal miRNAs in combination may be powerful for determining IS stage. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Ischemic stroke; biomarker; miR-125b-2-3p; miR-146a; miR-422a; plasma exosomes

Mesh:

Substances:

Year:  2017        PMID: 28982331     DOI: 10.2174/1567202614666171005153434

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  27 in total

Review 1.  Exosome-mediated amplification of endogenous brain repair mechanisms and brain and systemic organ interaction in modulating neurological outcome after stroke.

Authors:  Poornima Venkat; Jieli Chen; Michael Chopp
Journal:  J Cereb Blood Flow Metab       Date:  2018-06-11       Impact factor: 6.200

Review 2.  The role of exosomal microRNAs in central nervous system diseases.

Authors:  Yifei Yu; Kun Hou; Tong Ji; Xishu Wang; Yining Liu; Yangyang Zheng; Jinying Xu; Yi Hou; Guangfan Chi
Journal:  Mol Cell Biochem       Date:  2021-01-29       Impact factor: 3.396

Review 3.  Exosomal miRNAs in central nervous system diseases: biomarkers, pathological mediators, protective factors and therapeutic agents.

Authors:  Xiaohuan Xia; Yi Wang; Yunlong Huang; Han Zhang; Hongfang Lu; Jialin C Zheng
Journal:  Prog Neurobiol       Date:  2019-09-19       Impact factor: 11.685

Review 4.  Extracellular Vesicle Application as a Novel Therapeutic Strategy for Ischemic Stroke.

Authors:  Yiyang Li; Bowen Liu; Ying Chen; Xingping Quan; Yan Han; Ying Zheng; Yonghua Zhao
Journal:  Transl Stroke Res       Date:  2021-05-13       Impact factor: 6.829

5.  Increased serum exosomal miR-134 expression in the acute ischemic stroke patients.

Authors:  Jingxia Zhou; Lin Chen; Bocan Chen; Shaozhu Huang; Chaosheng Zeng; Hairong Wu; Cong Chen; Faqing Long
Journal:  BMC Neurol       Date:  2018-12-04       Impact factor: 2.474

6.  Advances in the diagnosis of exosomal miRNAs in ischemic stroke.

Authors:  Pei Yu; Wencheng Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-19       Impact factor: 2.570

7.  Altered Extracellular Vesicle MicroRNA Expression in Ischemic Stroke and Small Vessel Disease.

Authors:  Josie C van Kralingen; Aisling McFall; Emily N J Ord; Thomas F Coyle; Maria Bissett; John D McClure; Christopher McCabe; I Mhairi Macrae; Jesse Dawson; Lorraine M Work
Journal:  Transl Stroke Res       Date:  2019-01-07       Impact factor: 6.829

Review 8.  Potential of Exosomes for the Treatment of Stroke.

Authors:  Shi-Bin Hong; Hua Yang; Anatol Manaenko; Jianfei Lu; Qiyong Mei; Qin Hu
Journal:  Cell Transplant       Date:  2018-12-06       Impact factor: 4.064

9.  Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2.

Authors:  Yiming Deng; Duanduan Chen; Feng Gao; Hong Lv; Guojun Zhang; Xuan Sun; Lian Liu; Dapeng Mo; Ning Ma; Ligang Song; Xiaochuan Huo; Tianyi Yan; Jingbo Zhang; Zhongrong Miao
Journal:  J Biol Eng       Date:  2019-08-28       Impact factor: 4.355

Review 10.  Stem Cell-Derived Exosome in Cardiovascular Diseases: Macro Roles of Micro Particles.

Authors:  Ye Yuan; Weijie Du; Jiaqi Liu; Wenya Ma; Lai Zhang; Zhimin Du; Benzhi Cai
Journal:  Front Pharmacol       Date:  2018-05-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.